🔗 Share this article

While the US undertakes unprecedented changes to its vaccine schedules, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who rose to prominence by casting doubt on Covid vaccinations during the pandemic and has zeroed in on possible fatalities after Covid vaccination in her short position at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Vaccine Program

Public health authorities were set to reveal major changes to the childhood vaccination calendar earlier this month, synchronizing the US with Denmark’s vaccine program, sources say – a major change that would put the US out of step with much of the world with little proof for benefit. The announcement has been pushed back until the next year.

Rather than the top vaccines chief, Dr. Høeg is listed to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth person to lead the center this year.

A Shift at the FDA

Høeg's temporary position could signify a closer partnership between the drug and biologics divisions as Høeg and Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon dismantling previously authorized immunizations at the FDA.

Høeg has repeatedly called for discontinuing specific pediatric shot schedules in the US in order to be more similar to Denmark's approach, a country with universal health coverage and a citizenry roughly the size of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on vaccines – traditionally the responsibility of Dr. Prasad, director of the FDA’s vaccine center – rather than pharmaceutical oversight.

Concerns Over Background

The appointee has no obvious experience in pharmaceutical research, oversight or management, which has been typical for previous heads of the CBER. She has been employed at the FDA as a senior adviser to the agency head and CBER since March.

“She appears not to have any of the qualifications” for running the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in managing a large organization. She has no expertise in industry regulation.”

Former heads of CBER would “understand regulatory frameworks and the science of medication creation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that prior appointees who ran the center have had.”

The drug center has an vast workload at the agency, she pointed out.

“The public just zeroes in on the new drug program, but the generic program approves thousands of generic medications. There is also a biosimilars program, OTC medication office and more, and every single one must be looked after,” Woodcock said. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a significant leadership component to the position, which supervises more than 5,000 employees. “It’s a huge management job, if you perform it correctly,” the former official added.

Agency Reaction and Disputed Policies

In response to questions about Dr. Høeg's fitness for the role and whether this appointment indicates more teamwork among agency officials on immunizations, a press secretary stated that the “questions stem from incorrect assumptions”.

“Her experience aligns with the duties of her role,” the spokesperson stated, pointing to the period Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg takes over the agency head's new fast-track approval initiative, a controversial one-day drug-approval program that reportedly troubled her former heads. “By what process are these therapies being chosen for this fast-track system? Who is making the calls?” Dr. Howard questioned. “There is a lot of secrecy occurring at the FDA right now.”

Broadly speaking, he said, “the FDA looks to be trending towards more relaxed rules of all drugs, except for shots.”

Established Track Record on Immunizations

With vaccines, Dr. Høeg has a more established, if problematic, track record, Howard said. She authored a research paper using unconfirmed public submissions to determine the incidence of heart inflammation after COVID-19 vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccines are more dangerous than they are.

Included in her “policy goals” for the incoming federal leadership featured altering rules for recently developed shots and discontinuing “non-essential” immunizations, she said following the vote on a online show. At the agency, Dr. Høeg has according to sources suggested excluding teenage boys from obtaining COVID-19 vaccinations.

“She’s an all-around true believer who starts off with her preconceived notions and works backwards to retrofit the science in a extremely misleading, untruthful manner,” Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with other contrarians, {like|